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in nodal staging of non–small-cell lung 
cancer (NSCLC). We want to evaluate 
the accuracy of EBUS-TBNA and medi-
astinoscopy for nodal staging. The 2-year 
result of 138 consecutive patients was 
that EBUS-TBNA was superior to medi-
astinoscopy. Previous study to compare 
the EBUS-TBNA with mediastinoscopy 
showed no advantage to mediastinos-
copy,1 and later prospective randomized 
trial showed that the accuracy of EBUS 
was similar to mediastinoscopy.2
In addition, meta-analysis of 
11 EBUS-TBNA studies reported the 
sensitivity of 93% and a specificity of 
100%, which are superior to medias-
tinoscopy. There were meta-analysis 
papers for the complication rate, 
showing EBUS-TBNA of 0.05%,3 
compared with mediastinoscopy of 
2%.4 The cost-effectiveness of EBUS-
TBNA was analyzed to be lower 
mean cost and greater mean quality-
adjusted life years compared with 
mediastinoscopy.5
There are increasing train-
ing opportunities for EBUS-TBNA. 
World Association of Bronchology 
and Interventional Pulmonology has 
actively spreading the educational activ-
ities around the world and American 
College of Chest Physicians (ACCP) 
and local Bronchology Societies. 
American Thoracic Society, European 
Respiratory Society, and ACCP recom-
mend that 40 supervised procedures for 
initial training and 20 procedures per 
year to maintain competency. As the 
training activity of EBUS-TBNA are 
increasing, training accessibility will be 
better and better. ACCP and European 
Society of Thoracic Surgeons guide-
lines recommend that EBUS-TBNA 
should be first applied for nodal staging 
of NSCLC.
In conclusion, it is an irresistible 
trend that EBUS-TBNA is the first and 
the best procedure in the nodal staging 
of NSCLC.
Hojoong Kim, MD, PhD
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Critical Care Medicine
Department of Medicine, Samsung 
Medical Center
Sungkyunkwan University 
School of Medicine 
Seoul, Korea 
(extrapleural decortication, EP/D) main-
tained that less invasive techniques had to 
be preferred, given the comparable results 
in terms of long-term survival in several 
retrospective cohorts2 and the better early 
postoperative outlook. In the study by 
Bovolato et al3 that we read with interest 
and wish to discuss herein, the decision 
to perform EPP or EP/D was based on a 
careful assessment of the patient’s opera-
tive risk, the tumor staging, and the like-
lihood of completeness of the operation. 
Albeit introducing the clinical staging as 
the tool to drive the surgical indication, 
locally advanced MPM patients were 
treated mainly with EPP; an advantage in 
terms of survival is reported in pathologi-
cal stage IV patients (survival 28 months 
after EPP versus 10.9 months EP/D; 
p, 0.002) but not in earlier stages. One 
can speculate that this advantage is 
because of the fact that a bigger residual 
tumor is left when performing less inva-
sive operation in more advanced stages; 
however, this is an assumption worth of 
further and deeper investigation.
The ongoing dialogue in the sci-
entific community would recommend 
surgery for MPM only in the setting of 
research trials.4 Now, given this level 
of uncertainty, indeed based on the not 
homogeneous data available and the 
mostly retrospective nature of the stud-
ies reported so far, it would seem that the 
role of EPP should be further and care-
fully discussed to substantiate its role in 
“debulking” advanced diseases—more 
efficiently than lesser operations—and/
or treat, with curative intent, early ones.
In the study by Bovolato et al,3 
the best prognosis was detected in those 
patients younger than 70 years, with 
epithelioid MPM, who had received 
chemotherapy, but data failed to show 
a statistically significant advantage of 
surgical treatment overall versus non-
surgical one. Surprisingly, no statisti-
cally significant interaction was detected 
between the type of treatment and the 
clinical stages in terms of overall sur-
vival; anyway, Table 1 of Bovolato et al3 
shows that 51% and 38.9% of patients 
undergoing, respectively, EP/D and EPP 
had an unknown clinical stage, there-
fore setting a situation in which, likely, 
the extent of the surgical approach was 
decided intraoperatively. Correctly, 
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To the Editor:
The role of surgery in the manage-
ment of malignant pleural mesothelioma 
(MPM) is a forum of alive and kicking 
discussion: survival advantages stay 
substantially unproven. To the best of 
our knowledge, the Mesothelioma and 
Radical Surgery (MARS) study, so far the 
only prospective randomized trial whose 
results have been published in the English 
literature,1 concluded a negative outcome 
of extrapleural pneumonectomy (EPP) in 
a limited case series. On these evidences, 
advocates for lung-sparing approaches 
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advantages for extrapleural pneumo-
nectomy (EPP) compared with chemo-
therapy alone,1 although several biases 
had influenced those results.2 After the 
MARS trial was published, EPP has 
been abandoned in many European 
countries.
Recently, several series demon-
strated comparable or sometime better 
results for pleurectomy decortication 
(PD) compared with EPP in terms of 
overall survival and quality of life.3,4 
As showed by the paper published by 
Lang-Lazdunski et al., the macroscopic 
complete resection was an independent 
prognostic factor for survival and not 
the type of surgery, and also the group 
of patients underwent an incomplete 
resection after PD had similar results 
in terms of survival compared with 
patients underwent to EPP.3 Considering 
the role of surgery in mesothelioma 
multimodality treatment and the impact 
of EPP on the quality of life, PD should 
be favored compared with EPP as surgi-
cal treatment of choice. EPP is still per-
formed in very highly selected patients 
with no evidence of nodal disease and 
when a complete macroscopic resection 
can be achieved.1,3
Most of the patients included in 
our analysis were treated before the 
MARS trial results were available; 
at that time the decision of perform-
ing EPP versus PD was driven by the 
patient’s operative risk and mainly by 
the intraoperative assessment of the 
extension of the tumor to achieve aim-
ing a complete macroscopic esection.
As we know the clinical staging is 
unreliable, and many patients are under 
staged, making difficult the compari-
son of different groups.5,6 In our study, 
clinical staging was missing in 854 out 
of 1365 patients (62.6%); in patients 
not treated surgically the impact of 
missing data was higher (634 of 862 
[73.5%] patients). Due to lack of data 
and accuracy of the clinical staging, we 
did not include the clinical stage in the 
univariate and multivariate analysis. We 
do not believe that this a methodologi-
cal bias, but excluding this factor from 
the analysis had improved the quality of 
the comparison between the nonsurgi-
cal and the surgical groups. The clinical 
staging would have represented a con-
founding factor.
staging (in general) and the high propor-
tion of understaged or unstaged patient 
in their series; this, in our opinion, is a 
strong methodological bias with a high 
potential of hampering the subsequent 
multivariate analysis planned to dissect, 
in detail, the role of staging and surgi-
cal approach on survival. The flickering 
of values defining the role of pathologi-
cal stage as a prognostic factor in this 
series would recommend a cautious 
approach the coherence of the clinical 
and pathological TNM values, in par-
ticular regarding their capacity to predict 
the outcome—especially in the long-
term setting where curves do abate and 
flat—and by consequence to substanti-
ate, and thus justify, the indication for a 
more extensive surgical approach. More 
information around this issue would add 
precious knowledge on the natural his-
tory of the MPM, which is indeed pecu-
liar.5 We would furthermore appreciate a 
deeper analysis of the unstaged/under-
staged cases taken separately from those 
where data on staging where, preopera-
tively, complete. Anyway, if in the future 
only EP/D procedures will be offered 
to patients with MPM with “curative” 
or “palliative” intent (as in their con-
clusions Bovolato et al3 foresee) in the 
context of a multimodal treatment, what 
could be the usefulness of an extensive 
staging apart from excluding from sur-
gery patients with unresectable disease 
or with N-positive or M-positive status?
We would conclude constructively 
by inviting Bovolato et al3 to go deeper 
into the analysis in-line with the dis-
cussed points and provide the community 
with further interesting details. As well, 
we believe that experts’ dialogue—given 
the level of complexity of conflicting evi-
dences on this subject, in turn, generated 
by strong determinants as such as the het-
erogeneity of therapeutic choices—is still 
the best way to move on to resolve the 
large grey areas of knowledge for man-
agement and clinical decision in this field.
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To the Editor:
Carbonelli et al. made a very 
important point, focusing on the lack 
of evidence regarding the best surgi-
cal treatment to manage malignant 
pleural mesothelioma (MPM) patients. 
The only prospective randomized trial 
published in the literature showed no 
